Citations

Clear

590 citation(s) found for "Ho, Ben".

Smoothelin-B Deficiency Results in Reduced Arterial Contractility, Hypertension, and Cardiac Hypertrophy in Mice
Rensen, Sander S. , Niessen, Petra, Deursen, Jan M. van , Janssen, Ben, Heijman, Edwin , Hermeling, Evelien , Meens, Merlijn, Lie, Natascha, Gijbels, Marion J. , Strijkers, Gustav J. , Hofker, Marten H., Mey, Jo G. R. De , Eys, Guillaume J. van, Doevendans, Pieter A.

Mayo Clinic

Circulation | August 4, 2008 | Volume: 118 | Issue: 8 | Pages: 828-836

10.1161/circulationaha.107.743690 | PMID 18678771 Get It

Background— Smoothelins are actin-binding proteins that are abundantly expressed in healthy visceral (smoothelin-A) and vascular (smoothelin-B) smooth muscle. Their expression is strongly associated with the contractile phenotype of smooth muscle cells. Analysis of mice lacking both smoothelins ( Smtn-A/B −/− mice) previously revealed a critical role for smoothelin-A in intestinal smooth muscle contraction. Here, we report on the generation and cardiovascular phenotype of mice lacking only smoothelin-B ( Smtn-B −/− ). Methods and Results— Myograph studies revealed that the contractile capacity of the saphenous and femoral arteries was strongly reduced in Smtn-B −/− mice, regardless of the contractile agonist used to trigger contraction. Arteries from Smtn-A/B −/− compound mutant mice exhibited a similar contractile deficit. Smtn-B −/− arteries had a normal architecture and expressed normal levels of other smooth muscle cell–specific genes, including smooth muscle myosin heavy chain, α-smooth muscle actin, and smooth muscle-calponin. Decreased contractility of Smtn-B −/− arteries was paradoxically accompanied by increased mean arterial pressure (20 mm Hg) and concomitant cardiac hypertrophy despite normal parasympathetic and sympathetic tone in Smtn-B −/− mice. Magnetic resonance imaging experiments revealed that cardiac function was not changed, whereas distension of the proximal aorta during the cardiac cycle was increased in Smtn-B −/− mice. However, isobaric pulse wave velocity and pulse pressure measurements indicated normal aortic distensibility. Conclusions— Collectively, our results identify smoothelins as key determinants of arterial smooth muscle contractility and cardiovascular performance. Studies on mutations in the Smtn gene or alterations in smoothelin levels in connection to hypertension in humans are warranted.
Cyproheptadine displays preclinical activity in myeloma and leukemia
Mao, Xinliang , Liang, Sheng-Ben, Hurren, Rose, Gronda, Marcela, Chow, Sue, Xu, Gang , Zavareh, Reza Beheshti , Jamal, Nazir, Messner, Hans A., Hedley, David W. , Datti, Alessandro , Wrana, Jeffrey L. , Zhu, Yuanxiao, Shi, Chang-Xin, Tiedemann, Rodger E. , Trudel, Suzanne , Stewart, A. Keith , Schimmer, Aaron D. , Liang, Sheng‐Ben , Wang, Xiaoming , Lee, Kyle

Mayo Clinic

Blood | May 24, 2008 | Volume: 112 | Issue: 3 | Pages: 760-769

10.1182/blood-2008-02-142687 | PMID 18502826 Get It

AbstractD-cyclins are regulators of cell division that act in a complex with cyclin-dependent kinases to commit cells to a program of DNA replication. D-cyclins are overexpressed in many tumors, including multiple myeloma and leukemia, and contribute to disease progression and chemoresistance. To better understand the role and impact of D-cyclins in hematologic malignancies, we conducted a high throughput screen for inhibitors of the cyclin D2 promoter and identified the drug cyproheptadine. In myeloma and leukemia cells, cyproheptadine decreased expression of cyclins D1, D2, and D3 and arrested these cells in the G0/G1 phase. After D-cyclin suppression, cyproheptadine induced apoptosis in myeloma and leukemia cell lines and primary patient samples preferentially over normal hematopoietic cells. In mouse models of myeloma and leukemia, cyproheptadine inhibited tumor growth without significant toxicity. Cyproheptadine-induced apoptosis was preceded by activation of the mitochondrial pathway of caspase activation and was independent of the drug's known activity as an H1 histamine and serotonin receptor antagonist. Thus, cyproheptadine represents a lead for a novel therapeutic agent for the treatment of malignancy. Because the drug is well tolerated and already approved in multiple countries for clinical use as an antihistamine and appetite stimulant, it could be moved directly into clinical trials for cancer.
A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin
Mao, Xinliang , Stewart, A. Keith, Hurren, Rose, Datti, Alessandro , Zhu, Xuegong, Zhu, Yuanxiao, Shi, Chang‐Xin, Tiedemann, Rodger E. , Eberhard, Yanina, Trudel, Suzanne , Gillis, Lisa, Barber, Dwayne L. , Wrana, Jeffery L., Ezzat, Shereen , Schimmer, Aaron D. , Lee, Kyle , Liang, Sheng‐Ben , Corey, Seth Joel

Mayo Clinic

Blood | September 18, 2007 | Volume: 110 | Issue: 12 | Pages: 4047-4054

10.1182/blood-2007-05-088666 | PMID 17875808 Get It

AbstractThe oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators of c-maf, we developed a chemical screen in NIH3T3 cells stably overexpressing c-maf and the cyclin D2 promoter driving luciferase. From a screen of 2400 off-patent drugs and chemicals, we identified glucocorticoids as c-maf–dependent inhibitors of cyclin D2 transactivation. In multiple myeloma cell lines, glucocorticoids reduced levels of c-maf protein without influencing corresponding mRNA levels. Subsequent studies demonstrated that glucocorticoids increased ubiquitination-dependent degradation of c-maf and up-regulated ubiquitin C mRNA. Moreover, ectopic expression of ubiquitin C recapitulated the effects of glucocorticoids, demonstrating regulation of c-maf protein through the abundance of the ubiquitin substrate. Thus, using a chemical biology approach, we identified a novel mechanism of action of glucocorticoids and a novel mechanism by which levels of c-maf protein are regulated by the abundance of the ubiquitin substrate.
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
Richardson, Paul G. , Sonneveld, Pieter , Irwin, David, Stadtmauer, Edward A. , Harousseau, Jean‐Luc, Ben‐Yehuda, Dina, Goldschmidt, Hartmut , Reece, Donna , Bladé, Joan , Boccadoro, Mario , Cavenagh, Jamie, Alsina, Melissa , Rajkumar, S. Vincent , Lacy, Martha Q. , Dalton, William S. , Boral, Anthony, Esseltine, Dixie‐Lee, Schenkein, David P., Richardson, Paul Gerard Guy , Schuster, Michael K. , Facon, Thierry T.F. , Lonial, Sagar , Miguel, Jesús F. San , Jakubowiak, Andrzej , Anderson, Kenneth C. , Rajkumar, S Vincent

Mayo Clinic

Blood | August 9, 2007 | Volume: 110 | Issue: 10 | Pages: 3557-3560

10.1182/blood-2006-08-036947 | PMID 17690257 Get It

Abstract Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bortezomib versus high-dose dexamethasone. In this updated analysis (median follow-up: 22 months), survival was assessed in both arms, and efficacy updated for the bortezomib arm. Median survival was 29.8 months for bortezomib versus 23.7 months for dexamethasone, a 6-month benefit, despite substantial crossover from dexamethasone to bortezomib. Overall and complete response rates with bortezomib were 43% and 9%, respectively; among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response. Higher response quality (100% M-protein reduction) was associated with longer response duration; response duration was not associated with time to response. These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy. This study is registered at http://clinicaltrials.gov (Study ID NCT00048230).
The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan
Trudel, Suzanne , Stewart, A. Keith , Li, Zhihua , Shu, Yanjun, Liang, Sheng-Ben, Trieu, Young, Reece, Donna , Paterson, Josh, Wang, Dingyan , Wen, Xiao‐Yan , Liang, Sheng‐Ben , Wen, Xiao-Yan

Mayo Clinic

Clinical Cancer Research | January 25, 2007 | Volume: 13 | Issue: 2 | Pages: 621-629

10.1158/1078-0432.ccr-06-1526 | PMID 17255285 Get It

Abstract Purpose: The aim of this study is to investigate the antimyeloma activity of a novel Bcl-2 family inhibitor, ABT-737, in preclinical treatment of multiple myeloma. Experimental Design: The antimyeloma activity of ABT-737 was evaluated in cultured myeloma cell lines and patient myeloma samples, and in a xenograft mouse myeloma model. Drug combination therapy using ABT-737 with other commonly used myeloma drugs was also investigated. Results: MY5 and JJN3 cell lines exhibited the most sensitivity to ABT-737 with an EC50 of 0.2 and 0.5 μmol/L, respectively, with increased cell apoptosis and elevated activated caspase-3. We identified two distinct groups of myeloma patient samples that were either sensitive or resistant to the drug. Four of 15 patient bone marrow samples (27%) were highly sensitive to ABT-737 at doses of 0.25 and 0.5 μmol/L, which eliminated 80% to 90% of myeloma cells as a result of cellular apoptosis 3 days after drug treatment. ABT-737 showed a synergistic effect when combined with dexamethasone or melphalan in inducing myeloma cell death. Furthermore, the dexamethasone-resistant MM1(Dex)R myeloma cell line was highly sensitive to 0.2 μmol/L ABT-737. As determined by colony assay, little or no detectable toxicity to patient hematologic progenitor cells was observed at 1 μmol/L ABT-737. ABT-737 dose dependently suppressed tumor growth in a xenograft MY5 mouse model. Conclusions: These studies show substantial antimyeloma activity of ABT-737 as a single agent or in combination with dexamethasone or melphalan and suggest a rationale for future clinical trials.
Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model
Abrey, Lauren E. , Ben‐Porat, Leah, Panageas, Katherine S. , Curran, Walter J. , Schultz, Christopher J. , Leibel, Steven A., Nelson, Diana F., Mehta, Minesh P. , DeAngelis, Lisa M. , Price, Leah , Yahalom, Joachim , Berkey, Brian A. , Mehta, Minesh P , Price, Leah

Mayo Clinic

Journal of Clinical Oncology | November 21, 2006 | Volume: 24 | Issue: 36 | Pages: 5711-5715

10.1200/jco.2006.08.2941 | PMID 17116938 Get It

Purpose The purpose of this study was to analyze prognostic factors for patients with newly diagnosed primary CNS lymphoma (PCNSL) in order to establish a predictive model that could be applied to the care of patients and the design of prospective clinical trials. Patients and Methods Three hundred thirty-eight consecutive patients with newly diagnosed PCNSL seen at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY) between 1983 and 2003 were analyzed. Standard univariate and multivariate analyses were performed. In addition, a formal cut point analysis was used to determine the most statistically significant cut point for age. Recursive partitioning analysis (RPA) was used to create independent prognostic classes. An external validation set obtained from three prospective Radiation Therapy Oncology Group (RTOG) PCNSL clinical trials was used to test the RPA classification. Results Age and performance status were the only variables identified on standard multivariate analysis. Cut point analysis of age determined that patients age ≤ 50 years had significantly improved outcome compared with older patients. RPA of 282 patients identified three distinct prognostic classes: class 1 (patients < 50 years), class 2 (patients ≥50; Karnofsky performance score [KPS] ≥ 70) and class 3 (patients ≥ 50; KPS < 70). These three classes significantly distinguished outcome with regard to both overall and failure-free survival. Analysis of the RTOG data set confirmed the validity of this classification. Conclusion The MSKCC prognostic score is a simple, statistically powerful model with universal applicability to patients with newly diagnosed PCNSL. We recommend that it be adopted for the management of newly diagnosed patients and incorporated into the design of prospective clinical trials.
Hyperbilirubinemia Among African American, Glucose-6-Phosphate Dehydrogenase-Deficient Neonates
Kaplan, Michael , Herschel, Marguerite, Hoyer, James D., Stevenson, David K. , Hammerman, Cathy

Mayo Clinic

Pediatrics | August 14, 2004 | Volume: 114 | Issue: 2 | Pages: e213-e219

10.1542/peds.114.2.e213 | PMID 15286259 Get It

Background. Although glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is prevalent in African Americans, their risk of associated neonatal hyperbilirubinemia has not been prospectively studied.Objective. To compare hemolysis and the risk of hyperbilirubinemia among African American, G-6-PD-deficient neonates (study group) and G-6-PD-normal control subjects.Methods. Consecutive, healthy, term and near-term, male neonates born to African American mothers comprised the patient cohort. G-6-PD testing was performed with umbilical cord blood samples. Routine management included measurement of the end tidal carbon monoxide level corrected for ambient carbon monoxide level (ETCOc) within 4 hours after delivery (assessment of hemolysis), ≥1 predischarge bilirubin determination, and additional bilirubin testing as clinically indicated. Indications for phototherapy were identical for study patients and control subjects. Neonates were monitored for the first 1 week of life. ETCOc results, the incidence of hyperbilirubinemia (defined as a transcutaneous or plasma total bilirubin concentration of ≥95th percentile for the hour of life), and the need for phototherapy were compared between the G-6-PD-deficient and G-6-PD-normal groups.Results. Five hundred male patients were enrolled, of whom 64 (12.8%) were G-6-PD-deficient. ETCOc values (median and interquartile range) were higher among G-6-PD-deficient neonates than among control neonates (2.4 ppm [2.0–2.9 ppm] vs 2.1 ppm [1.7–2.5 ppm]). More G-6-PD-deficient neonates developed hyperbilirubinemia than did control subjects (14 of 64, 21.9%, vs 29 of 436, 6.7%; relative risk: 3.27; 95% confidence interval: 1.83-5.86), whereas 13 (20.3%) met the criteria for phototherapy, compared with 25 control subjects (5.7%) (relative risk: 3.53; 95% confidence interval: 1.91-6.56). No cases of kernicterus were observed.Conclusions. Within the African American neonatal population, there is a subgroup of G-6-PD-deficient infants with elevated rates of hemolysis, a higher incidence of hyperbilirubinemia, and a greater requirement for phototherapy, compared with G-6-PD-normal control subjects. These newborns should be monitored vigilantly for the development of hyperbilirubinemia.
A Novel Antiinflammatory Maintains Glucocorticoid Efficacy with Reduced Side Effects
Coghlan, Michael J., Jacobson, Peer B., Lane, Ben, Nakane, Masaki , Lin, Chun Wei, Elmore, Steven W., Luly, Jay R., Carter, George W., Turner, Russell T. , Tyree, Curtis M., Hu, Junlian, Elgort, Marc , Rosen, Jon, Miner, Jeffrey N. , Lane, Benjamin C., Kym, Philip R.

Mayo Clinic

Molecular Endocrinology | April 25, 2003 | Volume: 17 | Issue: 5 | Pages: 860-869

10.1210/me.2002-0355 | PMID 12586843 Get It

Abstract Glucocorticoids (GCs) are commonly used to treat inflammatory disease; unfortunately, the long-term use of these steroids leads to a large number of debilitating side effects. The antiinflammatory effects of GCs are a result of GC receptor (GR)-mediated inhibition of expression of proinflammatory genes as well as GR-mediated activation of antiinflammatory genes. Similarly, side effects are most likely due to both activated and repressed GR target genes in affected tissues. An as yet unachieved pharmaceutical goal is the development of a compound capable of separating detrimental side effects from antiinflammatory activity. We describe the discovery and characterization of AL-438, a GR ligand that exhibits an altered gene regulation profile, able to repress and activate only a subset of the genes normally regulated by GCs. When tested in vivo, AL-438 retains full antiinflammatory efficacy and potency comparable to steroids but its negative effects on bone metabolism and glucose control are reduced at equivalently antiinflammatory doses. The mechanism underlying this selective in vitro and in vivo activity may be the result of differential cofactor recruitment in response to ligand. AL-438 reduces the interaction between GR and peroxisomal proliferator-activated receptor γ coactivator-1, a cofactor critical for steroid-mediated glucose up-regulation, while maintaining normal interactions with GR-interacting protein 1. This compound serves as a prototype for a unique, nonsteroidal alternative to conventional GCs in treating inflammatory disease.